Thymogen is a synthetic dipeptide (L-glutamyl-L-tryptophan) developed in Russia as an immune modulator. It has been used clinically in Russia since the 1980s for immune deficiency states, post-surgical recovery, and as an adjunct in infectious disease treatment. While widely prescribed in Russian medicine, it has minimal recognition in Western medical literature and no peer-reviewed English-language clinical trials meeting modern standards. Its mechanism is attributed to thymic function enhancement.
Category: Immune Modulator / Bioregulator. Evidence rating: D (animal/preclinical only).
Clinical status: Approved in Russia for clinical use. No Western regulatory approval. Very limited English-language evidence.
Thymogen is proposed to mimic the activity of endogenous thymic peptides, promoting T-cell maturation and differentiation. It reportedly modulates the T-helper/T-suppressor ratio, enhances natural killer cell activity, and stimulates interferon production. The precise molecular target is not…
Safety considerations: Reported as well-tolerated in Russian clinical use over several decades; Minimal side effects reported in Russian literature: occasional allergic reactions; No Western safety assessments or pharmacovigilance data.
Reviewed by the PeptideAtlas Editorial Team.
| Amino-acid sequence | Glu-Trp |
|---|---|
| Molecular weight | ~333.3 g/mol |
| Production method | synthetic |
| Anti-doping status | not-listed |
| US regulatory status | Not FDA-approved. Not recognized as a therapeutic agent. |
Yes, thymogen has been approved and used clinically in Russia since the 1980s. It is administered intranasally or by injection. It has no regulatory approval in any Western country.
The vast majority of thymogen research is published in Russian-language journals that are not peer-reviewed to international standards. No placebo-controlled RCTs in English-language literature exist. The claims cannot be independently verified from available Western sources.
Bioregulators are a class of short peptides developed in Russia by Professor Vladimir Khavinson, based on the theory that organ-specific peptide extracts can restore function to aging or damaged tissues. This concept is not widely accepted in Western medicine and lacks rigorous clinical validation.